The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

NovoTTF and Temozolomide for Glioblastoma

Steven A. Toms, MD
Published Online: 5:22 PM, Mon November 17, 2014
Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.

Clinical Pearls

  • Patients were randomized 2:1 to NovoTTF in combination with temozolomide (n = 210) or standard therapy (n = 105), which included surgery, radiation, and temozolomide.
  • Progression-free and overall survival were both enhanced with the addition of NovoTTF.
  • Anecdotally, Toms said, NovoTTF has been well-tolerated by patients.
Read more about this novel therapy > >

<<< View more from the 2014 SNO meeting

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.